Devicare, a digital therapeutics company and CataloniaBio & HealthTech member, is looking to speed growth and has launched a crowdfunding campaign to raise €1.5 million through the Capital Cell platform. In just one week, the company has raised 39% of its goal.
Devicare has developed a non-surgical treatment for renal lithiasis or kidney stones, called Lit-Control®, and has closed commercial deals in 30 countries with various pharmaceutical companies. The latest market they’ve entered is the United States, this May, under the framework of the American Urological Association 2019 Annual Meeting (AUA).
“We’re innovating in the field of urology. With Lit-Control®, we’re addressing a poorly met need and the product has got a warm reception from both the medical community and patients. Given its social impact, the talent of the management team and the potential profitability, we believe that investing in this crowdfunding campaign is an excellent opportunity for small investors, patrons, patients and people who are conscious of improving health,” explains Rosendo Garganta, founder and CEO of Devicare. Plus, as it is a more mature project than most biomedical companies, “the risk for investors is less and we can give them better guarantees of up to five times return on their investment.”
Kidney stones are the third most common urological condition and affect 10% of the population.
Comments